Table of Contents
Confirmatory Study 012
PPT Slide
Eligibility Criteria
PPT Slide
Pretreatment Characteristics (I)
Pretreatment Characteristics (II)
Survival
Updated Survival
Time to Progression
Secondary Endpoint: Response Rate
Hematologic Toxicities (I)
Hematologic Toxicities (II)
Gastrointestinal Toxicities
Mucosal Toxicities
Hand-Foot Syndrome
Liver Function Tests
Concomitant Medications
Percentage of Patients with Delays or Reductions
Dose Intensity
Conclusions
|
Author: Bristol-Myers Squibb Pharmaceutical Research Institute
|